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Summary 
We used gene targeting techniques to produce mice lacking the invariant chain associated with 
major histocompatibility  complex (MHC) class II molecules. Cells from these mice show a dramatic 
reduction in surface class II, resulting from both defective association of class II c~ and ~/chains 
and markedly decreased post-Golgi transport. The few class II ol/~ heterodimers reaching the 
cell surface behave as if empty or occupied by an easily displaced peptide, and display a distinct 
structure. Mutant spleen cells are defective in their ability to present intact protein antigens, 
but stimulate enhanced responses in the presence of peptides. These mutant mice have greatly 
reduced numbers of thymic and peripheral CD4 + T  cells. Overall,  this striking phenotype 
establishes that the invariant chain plays a critical role in regulating MHC class II expression 
and function in the intact animal. 
T 
he class II membrane glycoproteins encoded in the MHC 
expressed by B cells, macrophages, dendritic cells, and 
thymic epithelial cells present antigenic peptides to helper 
T lymphocytes and guide thymic selection of CD4 + T lym- 
phocytes. Mature class II molecules are heterodimers com- 
prised of the products of two closely linked genes, the c~ and 
chains. Highly polymorphic residues located in the NH2- 
terminal domains of both chains are accessible  to ligands bound 
within the peptide binding groove (1). Recent studies have 
shown that this site on class II molecules can accommodate 
peptides 15-20 amino acids in length lacking precisely defined 
NH2-  and/or  COOH-terminal  ends  (2-5).  It  has  been 
known for some time that presentation of exogenous pro- 
tein antigens in association  with MHC class II molecules 
involves antigen uptake, internalization, and proteolytic degra- 
dation in endocytic vesicles. Recent observations have strength- 
ened the idea that class II molecules selectively acquire pep- 
tides through the endocytic pathway. Thus, sequence analysis 
of the predominant peptides recovered from purified class II 
1 This work was undertaken as a collaborative project between three senior 
investigators,  who made equally important contributions to the various 
technical  and intellectual  aspects of these experiments. 
molecules indicates that these are derived from integral mem- 
brane proteins, surface receptors,  and exogenous serum pro- 
teins (2-5). 
The class II c~/~ heterodimers assembled shortly after syn- 
thesis in the endoplasmic reticulum (ER) are associated with 
a third polypeptide chain, the invariant chain, a highly con- 
served glycosylated type II membrane protein encoded by an 
unlinked gene (6-9). There is evidence that the invariant chain 
can associate with free o~ and B chains before dimer assembly 
(10-12). However, recent studies suggest that the formation 
of nine-subunit ol/8I complexes (13) involves the sequential 
addition of ol/B dimers to preexisting invariant chain trimers 
(14), The ol/8I complexes are extensively modified during 
export through the Golgi complex (7, 8), and subsequently 
transported to a peripheral endocytic compartment (12, 15-18), 
where exposure to acidic pH and/or proteolytic enzymes (19, 
20) results in the dissociation of invariant chain before ex- 
pression of fully mature class II heterodimers at the cell sur- 
face. Recent experiments have identified a targeting signal 
in the cytoplasmic tail of the invariant chain that is respon- 
sible for localization to endocytic vesicles (12, 21). The as- 
sociation with invariant chain has been shown to prevent pep- 
tide occupancy (11, 20, 22, 23), suggesting that removal of 
the invariant chain may be necessary for the acquisition of 
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previously exposed to the invariant chain possess the ability 
to bind peptide ligands  in vitro  (24). 
Although early studies demonstrated  substantial  surface 
expression of class II molecules in the absence of invariant 
chain (25, 26), subsequent work indicated that coexpression 
of the invariant  chain can markedly enhance class II trans- 
port (27, 28). Over recent years, there have been conflicting 
reports regarding a requirement for invariant chain for class 
II-restricted antigen presentation (29-34). The extent of in- 
variant chain dependency seems to vary according to the par- 
ticular T cell clone receptor avidity and/or antigenic specificity 
(32, 34), and may also reflect divergent activities mediated 
by distinct invariant chain polypeptides that arise due to al- 
ternative mRNA splicing (34, 35). In light of these complex 
results, and concerns about the physiological relevance of ob- 
servations made in  vitro using cell lines not normally ex- 
pressing class II molecules and invariant chain, a satisfactory 
picture of the role played by the invariant chain in regulating 
class II expression and/or peptide binding has not yet emerged. 
Reliable methods for introducing precise mutations into 
the mouse germline have recently been established (36).  To 
better understand  possible contribution(s)  of the invariant 
chain to the function of class II molecules under physiolog- 
ical conditions, we produced a null mutation at the invariant 
chain locus using homologous recombination in pluripotent 
embryonic stem (ES) z cells.  The absence of invariant  chain 
caused several striking changes in MHC class II structure and 
function. The present findings demonstrate that invariant chain 
plays a critical role in assembly, transport, and peptide acqui- 
sition by MHC class II molecules and in the development 
of CD4 + T  lymphocytes. 
Materials and Methods 
Construction of the Targeting Vector.  The 1.2-kb SalI-XhoI frag- 
ment from pMClneo (37) was subdoned into the SalI site ofpSP73 
(Promega Biotec, Madison,  WI) and the resultant  plasmid was 
digested with XhoI and HindIII.  We then  inserted  the 1.7-kb 
HindIII-XhoI fragment from MCltk (38). Genomic fragments were 
obtained from the AKR cosmid clone 10.7 (39). The 5' fragment 
corresponding  to bases -707  to  +242  was  isolated  by PCR 
amplification using oligonudeotide  primers containing HindlII re- 
striction  sites. The 0.95-kb  5' Ii fragment  was then inserted,  in 
the appropriate orientation,  into a unique HindIII site. Finally, the 
7.5-kb 3' Sad fragment, blunt ended, was cloned into the unique 
SalI site. The targeting vector containing the Sad fragment in the 
correct  orientation  was designated pSP73neotk5'3'Ii. 
Generation of  ES Cell Chimeras.  CCE ES cells (40), maintained 
on STOneo feeder cells, were transfected with 10/~g of ClaI linear- 
ized phsmid, plated, and selected in G418 and gancylovir as de- 
scribed (41). Drug-resistant  colonies were individually picked and 
expanded into duplicate 24-well trays. One set of clones was frozen, 
the remaining set harvested in 500/~1 DNA lysis buffer per well, 
and DNA extracted from pools of lysates (five  clones/pool) amplified 
2Abbreviations used in  tkis paper: ER,  endoplasmic reticulum; ES, 
embryonic stem; nt, nudeotide. 
in 50 #1 containing  1 mM of each deoxynucleoside triphosphate, 
1.5 U Taq polymerase (Perkin-Elmer Corp.,  Norwalk, CT), and 
primers as shown in Fig. 1 A. Amplification products were sepa- 
rated on a 0.8% agarose gel and visualized by ethidium bromide 
staining. Individual clones among the pools positive by PCR were 
then separately analyzed to identify recombinants.  For Southern 
blot analysis, DNA (10-20 #g) was digested to completion with 
SacI, separated on a 0.8% agarose gel, transferred to GeneScreen, 
and probed using a neo fragment or the 800-bp AluI fragment de- 
rived from genomic sequences 5' to the Ii targeting vector as shown 
in Fig.  1. 
Recombinant ES cell clones were used to generate chimeric mice 
after microinjection into either  MF1 or C57BL/6J blastocysts as 
described (42). Male chimeras were mated to C57BL/6J females 
to identify animals that transmitted the ES cell-derived agouti coat 
color marker. The F1 progeny were screened by PCR. The het- 
erozygotes were then intercrossed. F2 animals were genotyped by 
Southern blot analysis or, more routinely, by PCR using primers 
shown in Fig. 1, and the products of 1,400 bp (mutant allele) and 
1,108 bp (wild type allele) were visualized on agarose gels after 
ethidium  bromide  staining. 
Antibodies and Peptides.  Hybridomas 28-14-8 and 25-9-17 (43) 
were provided by Dr. Keiko Ozato (National Institutes of Health, 
Bethesda, MD). M5/114 (44) was from the American Type Cul- 
ture Collection (Rockville, MD). B22.249 (45) was from Dr. Ul- 
rich Hammerling (Sloan-Kettering Memorial Institute, New York). 
Y-Ae (46) and Y3P (47) were generously provided by Drs. Charles 
Janeway, Jr.  (Yale University Medical School, New Haven, CT) 
and Donal Murphy (New York State Department of Health,  A1- 
ban),, NY). In-1 (48) was from Dr, Ralph Steinman (The Rocke- 
feller University, New York). P4H5 (49) was from Dr. Pat Jones 
(Stanford University, Palo Alto, CA).  Rabbit chain-specific anti- 
bodies directed against determinants located in the cytoplasmic tails 
of the ce and ~ chains, respectively, have been described (50). The 
E~  52-68  and  HEL  46-61  peptides  were  provided  by Dr.  J. 
Coligan (Biological  Resources Branch, National Institute of Allergy 
and Infectious Diseases, NIH). The HEL 74-88 peptide was kindly 
provided by Dr. N. Shastri (University of Cahfornia, Berkeley, CA). 
lmraunofluorescence Analysis.  For single-color analysis, spleen cell 
suspensions were freshly prepared or harvested after overnight cul- 
ture at 37~  (5  x  106 cells/ml) in complete  RPMI  1640 sup- 
plemented as described (51) alone or in the presence of peptides 
(100 IxM). Cells were incubated with saturating amounts of biotin- 
conjugated  anti-I-A b antibodies followed by FITC-labeled avidin 
D, or with the anti-Ii chain mAb In-1 followed by FITC-conjugated 
goat F(ab')2 anti-mouse IgG (H  +  L), as indicated in the figure 
legends. Before staining with the In-1 antibody, cells were treated 
with  10% formalin for 10 rain at room temperature  and exten- 
sively washed with PBS containing 0.1% saponin as described (33). 
In this case, incubations  and all washing  steps were carried out 
at room temperature in the presence of saponin (0.1%). Fluores- 
cence was analyzed on an Epics C flow cytometer (Coulter Elec- 
tronics Inc., Hialeah, FL) (Figs. 2 and 3), or using a FACScan  | 
flow cytometer (Becton Dickinson  & Co., Mountain  View, CA) 
(Fig. 7), and data were displayed as cell number vs. log fluores- 
cence. Dead cells and erythrocytes were eliminated from the anal- 
ysis by appropriate gating. 
For three-color analysis, suspensions of thymocytes or lymph 
node calls were incubated on ice with anti-CD8-FITC,  anti-TCR- 
B-PE,  and biotinylated  anti-CD4,  followed by Streptavidin-Cy- 
Chrome  TM (all antibodies and Streptavidin-Cy-Chrome  TM were from 
Pharmingen,  San Diego,  CA).  Listmode data were collected for 
all three fluorescence channels using a FACScan  |  flow cytometer 
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Dead cells and nonlymphoid ceils  were excluded  from analysis  using 
gates based on scatter. Contour plots for CD4 vs. CD8 were gener- 
ated from the scatter-gated data. Single histogram plots of TCR-3 
expression for cells with defined levels of CD4 and CD8 expres- 
sion were generated using the gates indicated on the CD4 vs. CD8 
contour plots. 
RNAse Protection Assay.  A riboprobe vector suitable for the 
analysis  ofli mRNA was previously  described (33). Briefly, a 277-bp 
PstI-BgllI fragment comprising coding sequences from exon 6 (92 
nucleotides [nt]) and exon 6b (185 nt) was inserted  into PstI-BamH1- 
digested pGEM4 (Promega Biotec, Madison, WI). The resultant 
plasmid (pGEMIi41) was linearized with EcoRI and transcribed 
using T7 polymerase to yield the 321-nt Ii41 probe. Total cellular 
KNA  was  hybridized  overnight  at  45~  in  the  presence of 
3zP-labeled antisense RNA. Unprotected RNA was digested using 
RNAse A (40/~g/ml)  and RNAse T1 (2 #g/ml) for 60 min at 
30~  Samples were treated with SDS and proteinase K, twice ex- 
tracted with phenol/chloroform, ethanol precipitated, redissolved 
in buffer containing 80% formamide, and analyzed  by electropho- 
resis in a 6% polyacrylamide denaturing gel. 
Radiolabeling and Immunoprecipitation Experiments.  Biosynthetic 
and surface labeling, immunoprecipitations, and SDS-PAGE were 
carried out as described (52). Briefly, spleen cells pretreated with 
Tris-ammonium chloride to lyse red blood cells were washed with 
warm HBSS containing 2% FCS and antibiotics, and resuspended 
(2  x  107 cells/ml) in warm leucine-free  RPMI 1640 supplemented 
with 4 mM glutamine and 5% dialyzed FCS. After 1 h at 37~ 
[3H]leucine was added (250/zCi/ml) for 40 min. Cells were ei- 
ther immediately harvested, washed twice with ice-cold PBS, and 
the cell pellet was lysed in buffer containing 1% NP-40, 20 mM 
Tris-HC1, pH 7.5, 150 mM NaC1, 5 mM EDTA, 1 mM PMSF, 
and 10 #g/ml aprotinin. After incubation on ice for 15 min ex- 
tracts were cleared of nuclei and debris by centrifugation for 30 
min at 15,000 rpm. Alternatively, labeled cells were resuspended 
in a fivefold  excess  volume of  warm KPM11640 supplemented  with 
15% FCS and 10x  cold leucine, incubated at 37~  a further 4 h, 
harvested, and extracts prepared as above. Lysates  were routinely 
precleared once with rabbit anti-mouse IgG (H +  L) antibodies, 
twice with rabbit anti-rat IgG (H  +  L), and twice with protein 
A-agarose (Bethesda Research Laboratories, Gaithersburg, MD), 
before the addition of specific antibodies. In the case of rat mAbs 
M5/114 and In-l, secondary anti-rat IgG (H + L) antibodies were 
added to facilitate  recovery  of immune complexes. Immunoprecipi- 
totes were washed three times with buffer containing 0.05 M Tris- 
HC1, pH 8, 0.45 M NaC1, 0.5%  NP-40, 0.05%  Na azide, and 
1 #g/ml aprotinin, and then solubilized in Laemmli buffer con- 
taining 2% SDS and 2-ME by treatment either for 60 min at room 
temperature or by heating at 100~  for 10 min as indicated in the 
figure legends. Samples were analyzed by SDS-PAGE using 10% 
polyacrylamide  gels subsequently treated with EnHance (DuPont- 
NEN, Wilmington, DE), dried, and exposed to x-ray film. Alter- 
natively, for analysis  of surface proteins, freshly isolated spleen cells 
were kept at 40C and surface labeled with mI using lactoperoxi- 
dose and glucose oxidase. Iodinated cells were extensively  washed 
with ice-cold 10 mM KI in PBS, and lysates  prepared and analyzed 
as above. 
Antigen Presentation Assays.  I-Ab-restricted  T cell hybrids in- 
cluded BDK 11.1 specific for KLH (53), provided by Dr. P. Mar- 
rack (Howard Hughes Medical Institute, National Jewish Center, 
Denver, CO); 171.3 L3T4 + stimulated by the HEL peptide 74-88 
(54), given to us by Dr.  N.  Shastri (University of California, 
Berkeley, CA), and the E= 52-68-specific hybridoma 1H3.1 (5), 
kindly provided by Dr. A. Rudensky (University of Washington, 
Seattle, WA). IL-2 production was assessed by incubating T cells 
(5  x  10Vwell) with irradiated (2,000 rod) spleen cells (10S/well) 
in 200/A complete RPMI 1640 supplemented with 10% FCS, 0.1 
mM nonessential amino acids, 5  x  10 -5 M. 2-ME, and 2 mM 
glutamine, and increasing concentrations of antigen as indicated 
in Fig. 8. Supematants were collected after 24 h and assayed  for 
IL-2 content in a secondary culture using CTLL indicator cells. 
[3H]Thymidine incorporation was measured in the presence of 
diluted (1:4) primary supernatant. Results shown are mean cpm 
of duplicate cultures. 
The B61-34 T cell clone specific  for IgG2a of the a allotype has 
been described (51). Briefly, T cells were maintained by repeated 
antigen stimulation in the presence of irradiated (2,000 rad) syn- 
geneic C57BL/6 spleen cells followed by short periods of rest. To 
measure antigen-specific proliferation, rested T  cells (2  x  104 
cells/well) were incubated with irradiated (3,300 rad) spleen cells 
(l& cells/well) in 200/A of complete RPMI 1640 alone or in the 
presence of LPC1 myeloma protein (500/~g/ml) as described (51). 
After a 48-h culture period, clonal expansion was assessed by a 
16-18-h exposure to 1/~Ci [3H]thymidine. Results are expressed 
as mean cpm of triplicate cultures. 
Results 
Generation of  a NulI Mutation at the Invariant Chain Locus.  To 
disrupt the invariant chain gene in ES cells, a positive-nega- 
tive selection strategy was used. The targeting vector (Fig. 
1 A) contained 8.45  kb of genomic homology interrupted 
by the MClneopA cassette in the same transcriptional orien- 
tation. The HSV thymidine kinase gene was placed  at the 
5' end of the genomic homology to facilitate selection against 
random integration events  (38).  Replacement of the wild- 
type locus by homologous recombination should result in 
a 3.8-kb deletion removing the first intron and 11 nt ofexon 2. 
CCE ES cells were transfected with linearized plasmid DNA 
by electroporation and transformants selected in the presence 
of G418 and gancyclovir.  Surviving colonies were screened 
for homologous recombinants using PCR primers specific 
for the unique 5' junctional fragment in the targeted locus. 
From 1,600 drug-resistant colonies analyzed, we recovered 
six PCR-positive clones. Homologous recombination at the 
invariant chain locus and the absence of randomly integrated 
copies of the targeting vector were verified by Southern blot 
analysis using a probe external to the 5' Ii sequence and also 
using a neo probe (data not shown). All six clones showed 
the restriction pattern predicted for the correctly targeted al- 
lele. As the gancylovir counterselection provided an eight- 
fold enrichment, the frequency of homologous recombina- 
tion was •1  in 2,000 integration events. 
Three independent recombinant ES cell clones were in- 
jected into blastocysts  and gave rise  to male chimeras that 
transmitted the mutation to their offspring. The resultant 
heterozygous progeny were intercrossed to  generate mice 
homozygous for  the  mutation.  In  experiments  described 
below, we analyzed invariant chain--cl_efident  mice derived from 
two independent ES cell clones.  Genotyping of intercross 
progeny indicates that live-born homozygotes are recovered 
at the expected frequency (representative  data shown in Fig. 
1). For the most part, homozygous mutants raised under con- 
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the  invariant chain locus. (A)  Schematic 
representation of the wild-type and mutant 
alleles and the targeting  vector. (R and S) Po- 
sitions of EcoRI and SacI restriction sites, 
respectively. (B) Southern  blot analysis  of re- 
presentative  tail  biopsies. Male  and female  mice 
carrying the targeted allele  were intercrossed 
and  representative F2  progeny analyzed. 
Genomic  DNA was digested  with Sacl  and hy- 
bridized with the 5' flanking  probe. Positions 
of the 4.2-kb fragment  derived  from  the wild- 
type locus and the 14.5-kb fragment  derived 
from  the targeted  allele  are indicated.  (C) PCR 
screen genotyping the  same individuals as 
shown in B using oligonucleotide  primers 
specific for a 5' junction fragment  or a wild- 
type sequence contained  within the deletion 
to generate  1,450- or 1,100-bp products  derived 
from the mutant or the wild-type  locus. 
ventional  conditions  appeared  healthy.  Occasionally they 
showed symptoms of severe wasting, and homozygotes were 
generally smaller than littermates. 
Absence of Invariant Chain Expression in Homozygous Mu- 
tants.  To establish that the mutation generated a null allele, 
invariant chain expression was examined in cytoplasmic staining 
experiments using the In-1 mAb reactive  with an epitope 
located near the NH2 terminus. As shown in Fig.  2 A,  a 
discrete strongly positive subpopulation comprised of "~40% 
of wild-type spleen cells was clearly observed.  In contrast, 
there was no significant staining of mutant spleen cells. As 
documented below, the absence of invariant chain does not 
simply reflect decreased numbers of B cells. Similarly, immu- 
noprecipitation  experiments using In-1 (Fig. 2 B) or the P4H5 
mAb (data not shown) directed against the COOH-terminal 
segment demonstrated abundant levels of invariant chain pro- 
duced by wild-type cells and the absence of detectable ex- 
pression in cells from homozygous mutants. Precipitations 
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with  anti-class  I  (H-2D  b)  antibodies  showed  equivalent 
amounts of dass I molecules were present in mutant and wild- 
type cells. 
Although these results using In-1 and P4H5 mAbs strongly 
argue that disruption of the invariant chain locus created a 
null mutation, these serological reagents might fail to detect 
aberrant forms of the protein. Therefore we examined steady- 
state levels of Ii mRNA using an RNAse protection assay 
that distinguishes alternatively spliced forms of Ii mRNA. 
Thus, mRNA molecules encoding pli41,  in which exon 6b 
sequences are present, protect the full-length 277-nt fragment, 
whereas mRNA encoding pli31 protects a 92-nt fragment. 
As shown in Fig.  2 C, wild-type lymph node and thymus 
tissues express high levels of both Ii41 and Ii31 transcripts. 
In contrast, we observed  no significant signal using RNA 
from homozygous mutants (Fig. 2 C, and data not shown). 
As judged by strong hybridization to a mouse actin probe, 
all these samples contained approximately equal amounts of Figure  2.  Gene targeting results 
in the absence of invariant chain ex- 
pression. (A) Cytoplasmic staining 
using the In-1 mAb (48). Saponin- 
treated spleen cells from individual 
wild-type (1 and 2) or homozygous 
mutant  mice  (3  and 4)  were  in- 
cubated with In-1 mAb followed by 
FITC-conjugated goat anti-rat IgG 
and analyzed by FACS  ~  (/3) Bio- 
synthetic labeling and immunopre- 
cipitation analysis. Lysates of spleen 
cells  tabded  for  40  rain  with 
[3H]leucine  and  immunoprecipi- 
tated with the indicated mAbs were 
analyzed  by  SDS-PAGE  under 
reducing  conditions.  (C)  RNAse 
protection analysis. The pGEMIi41 
probe  was  hybridized  with  total 
RNA (10 #g) prepared from the in- 
dicated tissues. The arrows indicate 
the probe size and the positions of 
the predicted full-length  protected 
fragments.  Additionally,  a smaller 
product  is  observed due  to  over- 
digestion at a short (5 nt) AT-rich 
sequence located  at the 3' end of 
exon 6 (33). 
intact  mRNA  (data  not  shown).  Thus,  we conclude that 
homozygous mutants show drastically reduced Ii transcripts 
extending to this region of the locus. Taken together, these 
data demonstrate that disruption of the invariant chain gene 
results in  the absence of expression. 
Decreased Levels of MHC Class II Surface Expression.  Al- 
though not absolutely required for MHC class II surface ex- 
pression (25,  26),  the invariant chain can enhance intracel- 
lular transport (27, 28) and affect serological reactivity of class 
II molecules (28,  31, 33).  To determine whether the invar- 
iant chain regulates class II surface expression under physio- 
logic  conditions,  mutant  and  wLld-type spleen  cells  were 
stained  using  a  panel  of anti-I-A  b mAbs  and  analyzed by 
flow microfluorimetry. As shown in Fig. 3, a-c, mutant spleen 
cells exhibited markedly reduced levels  of I-A  b surface an- 
tigens as detected using several mAbs, including M5/114 (3 
chain specific), 25-9-17  (B chain specific), and Y-3P  (ol  + 
~/specific)  (55-57). Because similar results were obtained with 
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all these antibodies, a strong argument can be made that this 
reflects decreased amounts of total surface I-A  b rather  than 
a serological change. H-2D b class  I surface molecules (Fig. 
3 d) and surface Ig (data not shown) were expressed equally 
well by mutant and wild-type spleen cells. These results dem- 
onstrate that the invariant chain is necessary for optimal class 
II  surface expression by normal splenic B  cells. 
Defective Class II Assembly and Transport in the Absence of 
Invariant Chain.  Decreased levels of class II surface antigens 
could reflect the requirement for invariant chain at any one 
of several steps during class II biosynthesis and maturation. 
To test whether the invariant chain acts at an early stage in 
the class II biosynthetic pathway, we analyzed chain synthesis 
and subunit assembly. Both mutant and wild-type cells pro- 
duce similar amounts of class II o~ and 3  chains (Fig. 4). To 
specifically evaluate the ratios of free chains and stably assem- 
bled dimers, lysates prepared from pulse-labeled spleen cells 
were precleared using rabbit chain-specific antibodies directed M5/114 
i.i~3 
,~  ~ 
25-9-17 
Y-3P 
~ 4 
d B22-249  1~:,~ 1 
Log Fbo~scence  Intensity 
Figure 3.  FACS  |  analysis 
showing reduced levels of MHC 
class II surface expression. Spleno- 
cytes from individual wild-type (I 
and 2) or homozygous mutant (3 
and 4)  mice were stained  with 
biotin-conjugated mAbs followed 
by FITC-conjugated avidin. 
against determinants located in the cytoplasmic tails of the 
ol and/3 chains, respectively (Fig. 4 A), or in the experiment 
shown in Fig. 4 B with M5/114 mAb to remove preexisting 
o~//3 heterodimers. As expected in wild-type spleen cells, these 
antibodies all precipitated substantial amounts of cx/B dimers 
associated with invariant chain. Newly synthesized free cx 
and B chains were also observed. In contrast, mutant spleen 
cells showed markedly reduced amounts ofc~//3 heterodimers 
reactive with the M5/114 mAb. Increased amounts of free 
c~ and ~/chains were present in these cells, reflecting a de- 
creased rate of subunit assembly or the formation of unstable 
dimers. These results demonstrate that invariant chain plays 
a critical  role in promoting or maintaining MHC class II 
subunit interactions. 
In addition, the subsequent transport of the newly formed 
ol/B heterodimers was examined using spleen cells pulsed for 
40 min and chased for 4 h. As expected, under these condi- 
tions virtually all the I-A  b molecules produced by wild-type 
spleen cells are comprised of mature cx and/3 chains that have 
undergone N-linked  glycan maturation during transport 
through the medial-Golgi (Fig. 4, A and B). In contrast, the 
majority of class II molecules in mutant spleen cells, like those 
produced in invariant  chain-negative cell lines (27, 28), are 
comprised of immature ol and/3 chains showing no biochem- 
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ical evidence of having been exported past the c/s-Golgi. Con- 
focal immunofluorescence microscopy confirmed that class 
II molecules are predominantly  located within the endoplasmic 
reticulum (ER) of mutant B lymphocytes (data not shown). 
Thus, ef~cient transport and posttranslational maturation of 
newly formed o~//3 dimers requires the invariant chain under 
normal physiological  conditions. 
Structurally Distinct oJl3 Heterodimers at the Cell Surface. 
There is evidence that class II molecules undergo a structural 
transition during acquisition of peptide ligand, such that newly 
formed, invariant chain-associated odB heterodimers are un- 
stable in the presence of SDS, whereas a substantial fraction 
of mature, self-peptide-occupied  class II molecules are resis- 
tant to SDS-induced denaturation (24,  52,  58-60).  To ex- 
amine the formation of compact SDS-resistant  dimers, we 
evaluated the structure of mature I-A  b molecules produced 
by mutant spleen cells pulsed for 40 min and chased for 4 h. 
As shown in Fig.  5,  virtually all the I-A  b molecules pro- 
duced by wild-type spleen cells migrate as compact dimers 
at ",~56 kD. In marked contrast, no mature compact SDS-re- 
sistant dimers were produced by mutant spleen cells. Instead 
these experiments revealed the presence of a novel species of 
I-A  b molecules having a reduced mobility in SDS-PAGE, 
comprised of ot and 3 chains with mature complex glycans. 
This population seems to correspond to the so-called "floppy" 
od/3 heterodimers previously described by Dornmair et al. 
(61, 62). Because they were not previously observed in meta- 
bolic labeling experiments, and are generated upon exposure 
of compact dimers to low pH in the absence of peptide (59), 
these floppy molecules were thought to represent partially 
denatured compact dimers. An interesting possibility is that 
floppy dimers possess an empty peptide groove that adopts 
an extended conformation, and this may account for their 
decreased mobility. 
To directly evaluate whether the structurally distinct het- 
erodimers produced by mutant spleen cells are expressed at 
the cell surface, and the proportion of surface molecules ex- 
hibiting this novel conformation, surface proteins were directly 
12si labeled and analyzed by SDS-PAGE. As shown in Fig. 
6, virtually all the I-A  b surface molecules expressed by wild- 
type spleen cells migrated in the position expected for com- 
pact SDS-resistant  dimers.  In contrast, mutant spleen cells 
exhibited undetectable levels of stable compact dimers reac- 
tive with either Y-3P mAb (Fig. 6) or rabbit anti-/3 chain 
antibodies (data  not shown). Instead the few class II c~//3 
heterodimers that reached the cell surface exhibited a slightly 
reduced mobility in SDS-PAGE, as seen above in metabolic 
labeling experiments. These results confirm the conclusion 
that the invariant chain plays a critical role in guiding class 
II export and directly demonstrate that invariant chain affects 
the structure and peptide occupancy of mature class II mol- 
ecules. 
Class II Molecules Produced by Invariant Chain-deficient Mice 
Show Enhanced Peptide Binding.  Structurally distinct SDS- 
resistant cx//3 heterodimers produced by mutant spleen cells 
closely resembled floppy dimers generated in vitro by partial 
denaturation of compact dimers with accompanying  peptide 
loss (59, 61, 62). It was therefore of considerable interest to Figure 4.  Defective assembly of 
MHC class II molecules in the ab- 
sence of invariant chain. Cytoplas- 
mic extracts  were  prepared  from 
spleen cells pulse-labeled  for 40 min 
with [3H]leucine  and in some cases 
after  a 4-h chase period.  Class II 
molecules were immunoprecipitated 
with the M5/114  mAb or chain- 
specific  rabbit  antibodies  added 
directly to untreated lysates or ly- 
sates prepared from pulse-infected 
spleen cells and precleared as in- 
dicated. 
directly compare mutant and wild-type spleen cells for their 
ability to bind peptides. To measure bound peptide, we used 
the Y-A~ mAb described by Murphy, Janeway, and their as- 
sociates (46,  63) directed against  a determinant present on 
I-A  b molecules associated with the E~ 52-68  peptide.  Mu- 
tant and wild-type spleen cells were cultured at 37~  over- 
night  in  the  presence  of E~  52-68,  or  as  a  control  HEL 
46-61 peptide, and then stained with biotin-labeled antibodies 
followed  by  FITC-labeled  avidin,  and  analyzed  by  flow 
microfluorimetry.  As  shown  in  Fig.  7  a,  despite  reduced 
amounts  of  surface  I-A  b,  mutant  spleen  cells  bound 
significantly higher amounts of F~ 52-68 peptide as detected 
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with the Y-Ae mAb. This treatment had no effect on total 
surface I-A  b as detected using 25-9-17 mAb (Fig.  7 b),  nor 
was surface I-A  b expression enhanced in the presence of an- 
other  I-A  b binding  peptide  (Ii  85-99;  data  not  shown). 
Thus, in contrast to the class II c~/B heterodimers produced 
by wild-type spleen cells that are stably occupied with self- 
and serum-derived peptides, class  II molecules expressed in 
the absence of the invariant chain behave as if empty or oc- 
cupied by an easily displaced peptide. 
Defective  Presentation  of  Native Protein  Antigens and Enhanced 
Responses in the Presence  of Peptides.  Considering that class 
II molecules produced by mutant spleen cells fail to acquire a  Y-Ae 
b  25-9-17 
i  i  i 
Log Fluorescence Intensity 
Figure 7.  Invariant chain-deficient mice produce empty class lI mole- 
cules. Wild-type (I and 2) or mutant (3 and 4) spleen cells were cultured 
at 37~  overnight in the presence of E= 52-68 (2 and 4) or, as a control, 
HEL 46-61  (I and 3) peptides and then stained with the biotin-labeled 
antibodies followed by FITC-labeled avidin and analyzed by FACS  | 
Figure 5.  Absence of mature compact stable SDS-resistant dimers. Ly- 
sates of spleen cells labeled for 40 rain with [3H]leucine and chased for 
4 h in the presence of cold leucine were immunoprecipitated  with the in- 
dicated antibodies. Complexes solubilized at 100~  (B) or at room tem- 
perature (NB) were analyzed by SDS-PAGE under reducing conditions. 
C and F indicate the positions of compact and floppy o.//3 heterodiraers, 
respectively. 
tightly bound peptides during transport to the cell surface, 
it was of interest to evaluate the functional consequences with 
respect to class II-restricted antigen presentation. Irradiated 
spleen cells were assessed for their ability to stimulate IL-2 
production or T cell proliferation in the presence of a panel 
of I-Ab-restricted  T cells. As shown in Fig. 8, mutant spleen 
cells stimulated stronger responses in the presence of the al- 
ready processed peptides,  HEL  74-88  and E,~ 52-68,  but 
they failed to present the native protein antigens, KLH and 
IgG2a  a.  We  observed no  significant response  directed to- 
wards endogenous IgG2a  ~ (Fig.  8 B).  These findings sup- 
Fig-re 6.  Structurally distinct 
class II molecules on the cell sur- 
face.  Extracts  of  125I surface- 
labeled spleen cells  were immuno- 
precipitated  with  Y3P  mAb. 
Complexes  were  solubilized  at 
1000C (B) or at room tempera- 
ture (NB) and analyzed by SDS- 
PAGE  under reducing conditions. 
C and F indicate the positions of 
compact and floppy oY~ hetero- 
dimers, respectively. Please note 
cell surface raurine ~ chains label 
poorly with iodine. 
port the conclusion that MHC class II molecules produced 
in the absence of invariant chain do not efficiently acquire 
peptide ligands in endocytic vesicles during transport to the 
cell surface,  and are more accessible  to exogenously added 
peptides. 
Decreased  Numbers of CD4 +  8 -  T  Cells in the Thymus and 
Periphery.  MHC dass II molecules play a critical role in both 
thymic selection and peripheral expansion of CD4 + T lym- 
phocytes,  as  dearly  demonstrated  by  recent  experiments 
analyzing mice lacking MHC class II molecules (64, 65). As 
shown above, invariant chain-deficient mice exhibited mar- 
kedly decreased levels of class II expression and a dramatic 
change in peptide occupancy of class II surface antigens. We 
therefore  investigated  possible  effect(s)  on  CD4 +  T  cell 
maturation.  When thymocytes from homozygous mutant 
mice were triply stained with anti-CD4, anti-CD8, and anti- 
TCK mAbs, we observed a striking reduction in the numbers 
of mature CD4+8-TCR hi T  cells  (Fig.  9 A).  The residu- 
al  CD4§  hi  population  included  fully  mature 
cells  expressing  low  levels  of  heat-stable  antigen  (data 
not  shown).  In  contrast,  mature  thymocytes  with  a 
CD4+CD8-TCRraHSA l~ phenotype have not been detected 
in class II-deficient mice (64, 66). The number of immature 
CD4+CD81~  i"te~me~ate cells  (67)  present  in  invariant 
chain-deficient mice did not differ significantly from that seen 
in wild-type controls. We found that CD4 +  CD8 + thymo- 
cytes expressed slightly increased levels of  TCK, as is the case 
for class II-deficient mice. Invariant chain-deficient mice also 
show a marked reduction in the number of CD4 +  CD8-  T 
cells present in the periphery (Fig. 9 B). Although these results 
were obtained using lymph node cells,  decreased numbers 
of mature CD4 + T lymphocytes were similarly observed in 
experiments analyzing splenic T cells (data not shown), and 
in all the mutants analyzed (a total of five animals in inde- 
pendent experiments). These results extend previous work 
1706  Invariant  Chain-deficient Mice A 
40,000 
35,000 
30,000 
25,000 
20,000 
15,000 
10,000 
5,000 
0  "4F"  -  + 
0  0.01  0.03  0.1  0.3  1 
KLH (mg/mq 
B 
C57BL/6  (IgG2a  b) 
B.C-9  (IgG2a  a) 
129/Sv  (IgG2a  a  ) 
(129/Sv x C57BIJS)F2 
(129/$v X B.C-9)F2 
epmxiO  -4 
.......  -  II 
[] Medium 
￿9  IgG2a  a 
C  20,000 
18,000 
16,000 
14,000 
~:  12,000 
8" 10,000 
8,000 
6,000 
4,000 
2,000 
0 
0.23  0.7  2.2  6.7  20 
HEL 74-88 (~M) 
D 
6OOOO 
5OOOO 
4OO0O 
E 
2OOOO 
1OOOO 
0 
￿9  +/+ 
Ea 52-68 (~M) 
Figure 8.  Defective presentation  of native protein antigens and enhanced responses directed towards peptides. Irradiated spleen cells were added 
to cultures containing I-Ab-restricted T cells specific for the indicated antigens. (A, C, and D) Cuhure supernatants were assayed for IL-2 content in 
a secondary assay with CTLL cells. (B) Proliferation of IgG2a-specific T cells was measured as [3H]thymidine incorporation.  Responses in the presence 
of medium alone or added LPC1 myeloma protein (500/~g/ml) are shown. 
on positive selection and further indicate that coexpression 
of the invariant chain is necessary for the normal develop- 
ment of CD4 § T  cells. 
Discussion 
To evaluate the role ofinvariant chain under normal physi- 
ological conditions, we generated an invariant chain-deficient 
mouse strain by targeted gene disruption in embryonic stem 
cells. The dramatic effects on dass II structure and function 
described in this report are therefore specifically attributable 
to the absence ofinvariant chain. The present results demon- 
strate that invariant chain is a specialized and essential chap- 
erone, necessary for efficient production of ol/fl heterodimers, 
that plays a pivotal role in peptide capture, and thus ulti- 
mately guides the performance of class II molecules as ligands 
for CD4 + T  cells in the thymus and the periphery. 
Surprisingly, we found that the invariant chain functions 
at an early stage in class II biosynthesis promoting optimal 
class II assembly, though as predicted by earlier observations 
(25, 26), coexpression of the invariant chain is not absolutely 
required for subunit interactions. Indeed a likely possibility 
was that assembly of newly synthesized oL and fl chains might 
occur spontaneously due to the intrinsic affinity of certain 
a/fl pairs (24, 68-70). Consistent with this, there is evidence 
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that invariant chain trimers are assembled with preexisting 
ol/~ dimers (14). Additionally, recent experiments have demon- 
strated that conserved residues present in the transmembrane 
domains of c~ and ~ chains provide stability for subunit as- 
sociation (71). Unexpectedly, we observed significantly fewer 
dimers and consistently higher amounts of free c~ and ~ chains 
in mutant spleen cells. These results demonstrate for the first 
time that the invariant chain plays a critical role in the produc- 
tion and/or maintenance of o~/~ dimers under normal physi- 
ological conditions. 
Recent experiments have shown that the ER lumen is a 
highly dynamic environment where oligomeric proteins un- 
dergo continuous ATP-dependent folding, unfolding, and 
refolding (72).  Thus, the invariant chain may be necessary 
to prevent inappropriate disulfide bond formation and/or im- 
proper folding of the subunits. In this sense, the invariant 
chain may act as a true molecular chaperone promoting and 
stabilizing subunit interactions.  Consistent with this, Schaiff 
et al. (73) recently found ER resident stress proteins GRP94 
and ERp72 associated with HLA-DR molecules produced 
in the absence ofinvariant chain. Similarly, we observed that 
the majority of c~/~  heterodimers produced by invariant 
chain-defident mice failed to acquire complex N-linked glycans 
and showed no evidence of export past the c/s-Golgi com- 
plex.  In contrast, cr  complexes can escape EtL resident A  THYMUS 
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Figure  9.  Absence  of mature CD4 +  8- T cells in the 
thymus and periphery. (/1) The upper portion shows con- 
tour plots of thymocytes analyzed for CD4 and CD8 ex- 
pression. Numbers refer to the percentage of total cells 
found in each indicated gate. The lower portion  shows 
single-color histograms for TCR expression of the cells 
within each of the gates indicated on the contour map. 
(B) Lymph node cells analyzed for CD4 and CD8 ex- 
pression. 
chaperones that bind incompletely assembled and/or misfolded 
molecules. 
Perhaps invariant chain serves as the functional equivalent 
of peptide for class II molecules to stabilize subunit interac- 
tions.  It is known  that  peptide ligand  is necessary to pro- 
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mote the association of MHC  class I  heavy chain and Bzm 
light chain (74-76). The invariant chain may contact residues 
present  on both chains  (10-12),  perhaps located in or near 
the peptide binding  site. This association may be necessary 
to protect the otherwise exposed, empty groove from being recognized by ER resident proteins. This idea is supported 
by the observation that empty class II molecules produced 
in insect cells tend to aggregate, a property reversed upon 
occupancy of the peptide binding site  (24).  Additionally, 
haplotype-mismatched c~/B pairs are retained in the ER/cis- 
Golgi complex in the absence of invariant chain (27),  and 
the residues responsible for defective expression of these par- 
ticular c~//3 combinations are located within the peptide- 
binding groove (10, 56, 57). The ability of the invariant chain 
to interact with newly formed cr/B dimers in the absence 
of their folding into a mature structure may be essential to 
maintain an open conformation of the binding site ready for 
peptide occupancy. 
Recent work has shown that MHC class II molecules can 
undergo a structural transition during peptide acquisition such 
that they become resistant to SDS-induced denaturation (24, 
52, 58-60), allowing us to examine the contribution of in- 
variant chain to peptide occupancy in a T cell-independent 
manner. In the absence of invariant chain, there was no de- 
tectable  synthesis of mature compact SDS-resistant  dimers. 
Surprisingly, the few a/B heterodimers inefficiently  trans- 
ported to the cell surface displayed a reduced mobility in SDS- 
PAGE. In contrast to the unstable dimers produced by so- 
matic mutants exhibiting antigen processing defects (77-79), 
this novel SDS-resistant species closely resembles the so-caUed 
floppy dimers previously described by Dornmair et al. (61, 
62) generated upon exposure of compact dimers to low pH 
in the absence of peptide (59).  In the present study, these 
molecules were observed under physiological conditions in 
biosynthetic labeling experiments. 
It is possible that these structural differences in part reflect 
the  absence  of transport  to  peripheral endosomes where 
prolonged exposure to acidic pH, proteolytic enzymes, and/or 
additional factors may potentially affect subunit associations 
and the shape of the peptide-binding groove. Consistent with 
this, exposure to low pH has been shown to increase func- 
tional antigen presentation (80), the amount of peptide quan- 
titated in direct binding studies (81), as well as stable com- 
plex formation (59).  On the other hand, previous studies 
suggested that floppy molecules adopt an extended confor- 
mation accounting for their slower migration in SDS-PAGE 
due to the absence of a tightly associated peptide (59). Con- 
sistent with this, direct peptide binding studies and func- 
tional peptide presentation assays described in this report dem- 
onstrate that surface class II molecules produced by mutant 
cells behave as if empty, or occupied by an easily displaced 
peptide. 
In light of the evidence that the invariant chain serves to 
protect the peptide-binding groove and its removal by pro- 
teolytic cleavage in vitro promotes peptide occupancy (11, 
20, 22, 23), it was surprising that class II molecules produced 
by mutant spleen cells showed no evidence of stable peptide 
occupancy. Because invariant chain-deficient mice expressed 
normal levels of MHC class I surface antigens, it seems clear 
that peptides normally bound by class I molecules during 
constitutive export cannot function as appropriate MHC class 
II ligands. Numerous reports have described an endogenous 
class II-restricted antigen presentation pathway (82-87), and 
there is evidence that presentation of self-peptides  is inde- 
pendent of invariant chain coexpression (29, 33). On the other 
hand, the present data indicate that under physiological con- 
ditions, the majority of peptides presented in association with 
dass II molecules, including self-peptides and those derived 
from exogenous antigens, require invariant chain for their 
capture. We also observed defective presentation of intact pro- 
tein antigens, such as KLH and IgG2a, that depend on endo- 
cytic  processing.  Exceptional  antigens  such  as  RNAse, 
showing invariant chain-independent presentation (32), may 
gain access to class II molecules via a distinct pathway. Under 
physiological conditions, excess invariant chain (88, 89) may 
be necessary to insure that newly formed oL/B heterodimers 
are  quantitatively transported  to  endocytic vesicles, thus 
promoting selective interactions with peptides derived from 
internalized antigens. This intraceUular transport route avoids 
surface expression of empty molecules, and selects against oc- 
cupation by peptides present in the extracellular environment. 
The present experiments largely examined class II expres- 
sion by the predominant population of splenic B cells. Class 
II molecules and the invariant chain are coexpressed in di- 
verse cell types such as B cells, macrophages, dendritic cells, 
and Langerhans cells (90-92), and are also coordinately up- 
regulated in response to lymphokines (93-96).  We found that 
invariant chain-defident mice, like those entirely lacking MHC 
class II molecules, have greatly reduced numbers of CD4 + 
T cells. The present results therefore demonstrate a contri- 
bution of invariant  chain to class II expression by thymic 
stromal cells responsible for positive selection. Because in in- 
variant chain-deficient mice, class II expression was affected 
both quantitatively and qualitatively  in terms of structure 
and peptide occupancy, these mutations might affect thymic 
selection  by different mechanism(s). In sum, the invariant 
chain-deficient mouse strain described in this report should 
prove useful for analyzing functional consequences of invar- 
iant chain expression in diverse Ia + accessory cell popula- 
tions such as those responsible for thymic education, T-B 
cooperation, autoimmunity, and tissue graft rejection. 
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